Wire · founder news, decoded · opportunities
Kalshi to allow bets on clinical trials, FDA decisions | 1330 & 101.5 WHBL
Prediction market platform Kalshi is launching markets on clinical trial outcomes and FDA decisions in partnership with AppliedXL, allowing investors to bet on individual drug approvals rather than entire company performance. The pilot restricts trading to late-stage trials with criteria defined before results are published, and includes bets on Gilead cancer drugs, Summit's lung cancer therapy, and AriBio's Alzheimer's candidate.
This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.
The Wire takeaway
If you're building trial forecasting, patient recruitment, or trial data analytics for biotech, you now have a market mechanism that prices your predictions in real time—and will expose which forecasters are actually right. The money moving into prediction markets on drug approvals is the earliest signal of which clinical endpoints matter to capital.
Read the full story at whbl.com →
Topics: Digital Health · clinical-trials · prediction-markets · fda-decisions · drug-development · biotech-finance